Caribou Biosciences, INC 10-Q quarterly reports

Caribou Biosciences (CRBU) filed its Q2 2026 Form 10-Q, detailing ongoing clinical development for its CAR-T therapies, alongside financial results showing continued net losses and a reduction in operating expenses.

Caribou Biosciences reported a net loss of $27.5 million for Q3 2025, alongside positive clinical data for vispa-cel and CB-011, and strategic pipeline prioritization.

Caribou Biosciences reports increased losses and significant restructuring, discontinuing two clinical programs and reducing its workforce by 32% to focus on lead CAR-T candidates.

Caribou Biosciences reports a net loss of $39.991 million for Q1 2025 and announces strategic pipeline prioritization with workforce and cost reduction initiatives.

Caribou Biosciences' third-quarter report reveals a complex picture of financial challenges and clinical advancements in its CRISPR-based cell therapy programs.

Caribou Biosciences reported a net loss of $78.9 million for the first half of 2024, while advancing its allogeneic CAR-T cell therapy programs.

Caribou Biosciences reports a net loss of $41.2 million for the first quarter of 2024, alongside updates on its clinical programs and financial position.